Detalhe da pesquisa
1.
Sequential antigen loss and branching evolution in lymphoma after CD19- and CD20-targeted T-cell-redirecting therapy.
Blood
; 143(8): 685-696, 2024 Feb 22.
Artigo
Inglês
| MEDLINE | ID: mdl-37976456
2.
EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical endpoint for multiple myeloma.
Blood
; 2024 05 20.
Artigo
Inglês
| MEDLINE | ID: mdl-38768337
3.
The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma.
Blood
; 2024 May 10.
Artigo
Inglês
| MEDLINE | ID: mdl-38728430
4.
A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAFV600E-mutated multiple myeloma.
Blood
; 141(14): 1685-1690, 2023 04 06.
Artigo
Inglês
| MEDLINE | ID: mdl-36608320
5.
Resolving therapy resistance mechanisms in multiple myeloma by multiomics subclone analysis.
Blood
; 142(19): 1633-1646, 2023 11 09.
Artigo
Inglês
| MEDLINE | ID: mdl-37390336
6.
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma.
Lancet Oncol
; 25(5): e205-e216, 2024 05.
Artigo
Inglês
| MEDLINE | ID: mdl-38697166
7.
Reproducible Radiomics Features from Multi-MRI-Scanner Test-Retest-Study: Influence on Performance and Generalizability of Models.
J Magn Reson Imaging
; 2024 May 11.
Artigo
Inglês
| MEDLINE | ID: mdl-38733369
8.
Clonal hematopoiesis with DNMT3A and PPM1D mutations impairs regeneration in autologous stem cell transplant recipients.
Haematologica
; 108(12): 3308-3320, 2023 Dec 01.
Artigo
Inglês
| MEDLINE | ID: mdl-37381752
9.
Application of an artificial intelligence-based tool in [18F]FDG PET/CT for the assessment of bone marrow involvement in multiple myeloma.
Eur J Nucl Med Mol Imaging
; 50(12): 3697-3708, 2023 10.
Artigo
Inglês
| MEDLINE | ID: mdl-37493665
10.
Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials.
BMC Cancer
; 23(1): 1132, 2023 Nov 21.
Artigo
Inglês
| MEDLINE | ID: mdl-37990162
11.
Cyclophosphamide etoposide dexamethasone as salvage and bridging therapy in relapsed refractory and extramedullary multiple myeloma.
Hematol Oncol
; 41(3): 453-462, 2023 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-36680428
12.
(Smoldering) multiple myeloma: mismatch between tumor load estimated from bone marrow biopsy at iliac crest and tumor load shown by MRI.
Skeletal Radiol
; 52(12): 2513-2518, 2023 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-37300710
13.
Polymorphisms within Autophagy-Related Genes as Susceptibility Biomarkers for Multiple Myeloma: A Meta-Analysis of Three Large Cohorts and Functional Characterization.
Int J Mol Sci
; 24(10)2023 May 09.
Artigo
Inglês
| MEDLINE | ID: mdl-37239846
14.
Comprehensive genomic analysis of refractory multiple myeloma reveals a complex mutational landscape associated with drug resistance and novel therapeutic vulnerabilities.
Haematologica
; 107(8): 1891-1901, 2022 08 01.
Artigo
Inglês
| MEDLINE | ID: mdl-35045690
15.
Daratumumab in high-risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome.
Br J Haematol
; 189(1): 67-71, 2020 04.
Artigo
Inglês
| MEDLINE | ID: mdl-31820442
16.
When a solitary plasmacytoma is just the beginning .
Blood
; 142(22): 1849-1850, 2023 11 30.
Artigo
Inglês
| MEDLINE | ID: mdl-38032673
17.
The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma.
Blood
; 132(1): 59-66, 2018 07 05.
Artigo
Inglês
| MEDLINE | ID: mdl-29784643
18.
Transcriptome-wide association study of multiple myeloma identifies candidate susceptibility genes.
Hum Genomics
; 13(1): 37, 2019 08 20.
Artigo
Inglês
| MEDLINE | ID: mdl-31429796
19.
Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.
Biol Blood Marrow Transplant
; 25(3): e89-e97, 2019 03.
Artigo
Inglês
| MEDLINE | ID: mdl-30408566
20.
Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma.
Blood
; 130(1): 30-34, 2017 07 06.
Artigo
Inglês
| MEDLINE | ID: mdl-28432222